Page last updated: 2024-11-12
du1301
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
DU1301: an antimalarial drug that is effective against multidrug-resistant Plasmodium falciparum strains [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 16744610 |
CHEMBL ID | 427452 |
MeSH ID | M0489065 |
Synonyms (4)
Synonym |
---|
du1301 |
CHEMBL427452 |
6-isopropyl-n-[2-[(7-chloroquinoline-4-yl)amino]ethyl]-8abeta-methyl-4abeta,7,8,8a-tetrahydrospiro[1,2,4-benzotrioxin-3,1'-cyclohexane]-4'-amine |
n-[(4ar,8as)-8a-methyl-6-propan-2-ylspiro[7,8-dihydro-4ah-1,2,4-benzotrioxine-3,4'-cyclohexane]-1'-yl]-n'-(7-chloroquinolin-4-yl)ethane-1,2-diamine |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (15)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID285484 | Toxicity against Swiss mouse at 200 mg/kg, po after 4 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Trioxaquines are new antimalarial agents active on all erythrocytic forms, including gametocytes. |
AID285472 | Antimalarial activity against chloroquine-resistant Plasmodium falciparum FcM29 | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Trioxaquines are new antimalarial agents active on all erythrocytic forms, including gametocytes. |
AID285475 | Antimalarial activity against Plasmodium vinckei petteri infected orally dosed Swiss Albino mice (Mus musculus) | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Trioxaquines are new antimalarial agents active on all erythrocytic forms, including gametocytes. |
AID285470 | Antimalarial activity against chloroquine-sensitive Plasmodium falciparum Nigeria | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Trioxaquines are new antimalarial agents active on all erythrocytic forms, including gametocytes. |
AID285474 | Antimalarial activity against Plasmodium vinckei petteri infected intraperitoneally dosed Swiss Albino mice (Mus musculus) | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Trioxaquines are new antimalarial agents active on all erythrocytic forms, including gametocytes. |
AID285471 | Antimalarial activity against chloroquine-resistant Plasmodium falciparum FcB1 | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Trioxaquines are new antimalarial agents active on all erythrocytic forms, including gametocytes. |
AID285473 | Cytotoxicity against human HCT cells assessed as [3H]thymidine incorporation | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Trioxaquines are new antimalarial agents active on all erythrocytic forms, including gametocytes. |
AID285476 | Antimalarial activity against Plasmodium vinckei petteri infected subcutaneously dosed Swiss Albino mice (Mus musculus) | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Trioxaquines are new antimalarial agents active on all erythrocytic forms, including gametocytes. |
AID531312 | Induction of heme alkylation in Plasmodium vinckei petteri-infected Swiss albino mice (Mus musculus) kidney assessed as heme-drug adduct at 100 mg/kg, perorally administered as single dose measured by liquid chromatography-mass spectrometry method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | The antimalarial trioxaquine DU1301 alkylates heme in malaria-infected mice. |
AID285491 | Antimalarial activity against Plasmodium vinckei petteri infected mice (Mus musculus) at 13 mg/kg/day, peroral administered 4 days after infection for 4 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Trioxaquines are new antimalarial agents active on all erythrocytic forms, including gametocytes. |
AID285485 | Toxicity against Swiss mouse at 400 mg/kg, po after 4 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Trioxaquines are new antimalarial agents active on all erythrocytic forms, including gametocytes. |
AID531311 | Induction of heme alkylation in Plasmodium vinckei petteri-infected Swiss albino mice (Mus musculus) spleen assessed as covalent heme-drug adduct formation at 100 mg/kg, perorally administered as single dose measured by liquid chromatography-mass spectrom | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | The antimalarial trioxaquine DU1301 alkylates heme in malaria-infected mice. |
AID1688334 | Inhibition of beta-hematin assessed as heme alkylation at 2 molar equivalents incubated for 30 mins by HPLC analysis relative to control | 2020 | European journal of medicinal chemistry, Feb-15, Volume: 188 | Current progress in antimalarial pharmacotherapy and multi-target drug discovery. |
AID285469 | Antimalarial activity against chloroquine-sensitive Plasmodium falciparum F32 | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Trioxaquines are new antimalarial agents active on all erythrocytic forms, including gametocytes. |
AID285483 | Toxicity against Swiss mouse at 100 mg/kg, po after 4 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Trioxaquines are new antimalarial agents active on all erythrocytic forms, including gametocytes. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (6)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (83.33) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 24.70
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (24.70) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (16.67%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (83.33%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |